JP6659681B2 - 不眠症を治療するための組成物および方法 - Google Patents

不眠症を治療するための組成物および方法 Download PDF

Info

Publication number
JP6659681B2
JP6659681B2 JP2017522213A JP2017522213A JP6659681B2 JP 6659681 B2 JP6659681 B2 JP 6659681B2 JP 2017522213 A JP2017522213 A JP 2017522213A JP 2017522213 A JP2017522213 A JP 2017522213A JP 6659681 B2 JP6659681 B2 JP 6659681B2
Authority
JP
Japan
Prior art keywords
compound
once daily
effective amount
therapeutically effective
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017522213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531683A (ja
JP2017531683A5 (https=
Inventor
マーガレット モーリーン
マーガレット モーリーン
ジナ パスティーノ
ジナ パスティーノ
百合恵 秋本
百合恵 秋本
泰弘 財満
泰弘 財満
伸哉 鈴木
伸哉 鈴木
宜央 吉田
宜央 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2017531683A publication Critical patent/JP2017531683A/ja
Publication of JP2017531683A5 publication Critical patent/JP2017531683A5/ja
Application granted granted Critical
Publication of JP6659681B2 publication Critical patent/JP6659681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2017522213A 2014-10-23 2015-10-21 不眠症を治療するための組成物および方法 Active JP6659681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
US62/067,443 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (3)

Publication Number Publication Date
JP2017531683A JP2017531683A (ja) 2017-10-26
JP2017531683A5 JP2017531683A5 (https=) 2019-11-21
JP6659681B2 true JP6659681B2 (ja) 2020-03-04

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522213A Active JP6659681B2 (ja) 2014-10-23 2015-10-21 不眠症を治療するための組成物および方法

Country Status (14)

Country Link
US (3) US10188652B2 (https=)
EP (1) EP3209298B1 (https=)
JP (1) JP6659681B2 (https=)
KR (1) KR102444608B1 (https=)
CN (1) CN107810006B (https=)
AU (1) AU2015336463B2 (https=)
BR (1) BR112017007063A2 (https=)
CA (1) CA2964504C (https=)
ES (1) ES2843952T3 (https=)
IL (1) IL251759B (https=)
MX (1) MX376164B (https=)
RU (1) RU2703297C2 (https=)
SG (2) SG11201703064WA (https=)
WO (1) WO2016063995A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376164B (es) 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
CA3022068A1 (en) 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
BR112021026291A2 (pt) * 2019-06-26 2022-03-03 Eisai R&D Man Co Ltd Lemborexant para tratar problemas de sono
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
MX2022007304A (es) 2019-12-20 2022-08-22 Eisai R&D Man Co Ltd Uso de lemborexant para tratamiento del insomnio.
US20230103250A1 (en) * 2020-01-16 2023-03-30 Eisai R&D Management Co., Ltd. Drug substance of lemborexant and medicinal composition comprising same
US20230134935A1 (en) * 2020-04-19 2023-05-04 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
TW202425995A (zh) 2022-09-23 2024-07-01 日商衛材R&D企管股份有限公司 減少與神經退化疾病相關的神經退化的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
JP2008513434A (ja) 2004-09-23 2008-05-01 ファイザー・プロダクツ・インク トロンボポイエチン受容体アゴニスト
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
BRPI0716532A2 (pt) 2006-09-11 2013-09-24 Glaxo Group Ltd compostos azabicÍclios como inidores de reabsorÇço de monoaminas
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
MX2010002419A (es) 2007-09-21 2010-03-30 Sanofi Aventis (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP5735010B2 (ja) * 2010-02-15 2015-06-17 コーニンクレッカ フィリップス エヌ ヴェ 制御チャネル干渉の軽減
WO2012039371A1 (ja) * 2010-09-22 2012-03-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロプロパン化合物
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
MX376164B (es) 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.

Also Published As

Publication number Publication date
IL251759A0 (en) 2017-06-29
RU2017112308A (ru) 2018-11-26
US20200268754A1 (en) 2020-08-27
US20190201399A1 (en) 2019-07-04
CA2964504C (en) 2022-08-23
EP3209298B1 (en) 2020-12-02
IL251759B (en) 2021-01-31
EP3209298A1 (en) 2017-08-30
AU2015336463A1 (en) 2017-05-04
WO2016063995A1 (en) 2016-04-28
RU2703297C2 (ru) 2019-10-16
KR20170068478A (ko) 2017-06-19
AU2015336463B2 (en) 2020-06-18
EP3209298A4 (en) 2018-06-20
CN107810006A (zh) 2018-03-16
SG10202007759RA (en) 2020-09-29
MX376164B (es) 2025-03-07
SG11201703064WA (en) 2017-05-30
JP2017531683A (ja) 2017-10-26
ES2843952T3 (es) 2021-07-21
US10188652B2 (en) 2019-01-29
CN107810006B (zh) 2021-03-30
CA2964504A1 (en) 2016-04-28
US11026944B2 (en) 2021-06-08
BR112017007063A2 (pt) 2018-02-14
KR102444608B1 (ko) 2022-09-20
US20170252342A1 (en) 2017-09-07
RU2017112308A3 (https=) 2019-05-08
MX2017004950A (es) 2018-01-16
US10702529B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
JP6659681B2 (ja) 不眠症を治療するための組成物および方法
JP5914626B2 (ja) 徐放性アミノピリジン組成物の使用方法
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
US11427540B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
US11738002B2 (en) Methods of treating neurological and psychiatric disorders
JP2012229261A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
JP2019518732A (ja) 概日リズム睡眠障害群を治療する方法
CA3075872A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2021222342A1 (en) Methods of use of t-type calcium channel modulators
TW202308653A (zh) 以神經活性類固醇進行治療的方法
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
EA051790B1 (ru) Композиция кофеина с пульсирующим высвобождением

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180518

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200206

R150 Certificate of patent or registration of utility model

Ref document number: 6659681

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250